AHLA, American Health Lawyers Association
A A A
Home  |  Sign In  |  Contact Us  |  Job Bank
AHLA » News Center » Daily Archive » DOJ joins whistleblower suits against J&J for marketing off-label uses of its cardiac drug Leading health law to excellence through education, information and dialogue lktw
Follow AHLA  

In Daily Archive:

AHLA ConnectionsExpand AHLA Connections
Health Lawyers WeeklyExpand Health Lawyers Weekly
Health and Life Sciences Law Daily
Health Law Digest
Health Law Documents
Press RoomExpand Press Room
    
Print this page Print this page
Email to a friend Email to a friend

      

      

           Share this Page

 

DOJ joins whistleblower suits against J&J for marketing off-label uses of its cardiac drug 

The Wall Street Journal (2/20, Wang, Kendall) reports, "The U.S. Justice Department is joining two whistleblower lawsuits alleging that Johnson & Johnson [J&J] marketed its cardiac drug Natrecor [nesiritide] for a use that isn't approved by the Food and Drug Administration." The drug was approved in 2001 "for in-hospital use by patients with congestive heart failure." But, the prosecutors allege "that Scios, a subsidiary of J&J, launched an aggressive campaign to market Natrecor for patients with less-severe heart failure in an out-patient setting." In doing so, the company "caused 'false and fraudulent claims' to be submitted to federal healthcare programs, which could have led to 'damages in the hundreds of millions of dollars.'"

        According to the AP (2/20), the company was advised "to stop promoting Natrecor for patients with less sever heart failure, including those who are no longer hospitalized," in 2005 by "a panel of leading cardiologists." J&J then "released results of a study that showed no medical benefit for those patients" in 2007. The company now faces two whistleblower suits "filed in the Northern District of California by former sales managers for J&J unit Scios Inc."

        The Justice Department noted that "Medicare does not cover drugs used for off-label uses unless such off-label use is established to be medically necessary," but that it "paid substantial amounts for the serial outpatient off-label use," Bloomberg News (2/20, Blum) adds. As a result, prosecutors "could seek damages as much as triple the cost of the off-label medicines, as well as $5,500 to $11,000 for each false or fraudulent reimbursement claim filed." A J&J spokesman stated that the company "has 'reviewed the allegations thoroughly and will address them in the courts.'"

        Modern Healthcare (2/20, Blesch) noted that "the Justice Department did not specify the cost of the alleged false claims and has not yet filed its version of the complaint." The San Francisco Chronicle (2/19, Egelko) and the Dow Jones Newswires (2/20, Kendall, Favole) also covered the story.

 

Copyright © 2008 by Custom Briefings | 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191


 
Related Resources
© 2012 American Health Lawyers Association
1620 Eye Street NW
Washington, DC  20006-4010
Phone: 202-833-1100   Fax: 202-833-1105
FAQ  |  Privacy Policy  |  Site Map